Trial · NCT03397121
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in LDL-C From Baseline To Day 510 | Inclisiran | -41.15 | 95% Confidence Interval -44.52 to -37.77 | percent change | |
| Percent Change in LDL-C From Baseline To Day 510 | Placebo | 8.37 | 95% Confidence Interval 3.96 to 12.77 | percent change | |
| Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 540 | Inclisiran | -38.08 | 95% Confidence Interval -41.03 to -35.14 | percent change | |
| Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 540 | Placebo | 6.22 | 95% Confidence Interval 3.26 to 9.17 | percent change | |
| Absolute Change in LDL-C From Baseline to Day 510 | Inclisiran | -58.95 | 95% Confidence Interval -64.75 to -53.15 | mg/dL | |
| Absolute Change in LDL-C From Baseline to Day 510 | Placebo | 9.94 | 95% Confidence Interval 4.10 to 15.78 | mg/dL | |
| Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540 | Inclisiran | -56.58 | 95% Confidence Interval -60.98 to -52.17 | mg/dL | |
| Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540 | Placebo | 6.17 | 95% Confidence Interval 1.72 to 10.62 | mg/dL | |
| Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510 | Inclisiran | -60.68 | 95% Confidence Interval -64.40 to -56.96 | percent change | |
| Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510 | Placebo | 17.66 | 95% Confidence Interval 13.91 to 21.42 | percent change | |
| Percentage Change in Total Cholesterol From Baseline to Day 510 | Inclisiran | -25.11 | 95% Confidence Interval -27.83 to -22.39 | percent change | |
| Percentage Change in Total Cholesterol From Baseline to Day 510 | Placebo | 6.66 | 95% Confidence Interval 3.96 to 9.36 | percent change | |
| Percent Change in Apolipoprotein B (Apo-B) From Baseline To Day 510 | Inclisiran | -33.14 | 95% Confidence Interval -35.91 to -30.36 | percent change | |
| Percent Change in Apolipoprotein B (Apo-B) From Baseline To Day 510 | Placebo | 2.93 | 95% Confidence Interval 0.14 to 5.71 | percent change | |
| Percent Change in Non-high-density Lipoprotein (HDL)-C From Baseline To Day 510 | Inclisiran | -34.93 | 95% Confidence Interval -38.46 to -31.40 | percent change | |
| Percent Change in Non-high-density Lipoprotein (HDL)-C From Baseline To Day 510 | Placebo | 7.43 | 95% Confidence Interval 3.93 to 10.92 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03397121/results